NEW YORK (GenomeWeb News) — Molecular diagnostics company Source MDx today said it will work with Pfizer to uncover biomarkers linked to response and resistance to certain of the drug giant’s cancer and inflammatory candidate compounds.
 
As part of the multi-year alliance, the firms will use genomic and RNA transcription profiling to identify inflammation and cancer-related biomarkers in whole blood and circulating rare cells.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.